Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

Controlled Randomized Double-blind Study Comparing Salbutamol and Placebo Via Aerosol in Chronic Obstructive Respiratory Insufficiency in Exacerbartion Treated With Noninvasive Ventilation

randomized double-blind controlled study in parallel groups

Salbutamol is a β2 mimetic short-acting to be administered by nebulization in this study.

During this administration, non invasive ventilation for the patient will be continued.

Randomization will focus on the treatment administered (placebo or salbutamol ).

After the first phase , a switch will be set up for each patient , retaining the blind it will be administered salbutamol (for those who received placebo in the first phase ) or placebo (for those receiving salbutamol ) .

Inclusion Criteria:

• Patient over 18 years old

• Patient with BPCO, defined:

  • by an irreversible obstructive syndrome
  • and\or by different arguments (histories, symptoms, physical examination, thoracic radiography, gas of the blood)

• Decompensation of this BPCO in the form of acute respiratory failure

• No argument for a dominant acute left cardiac insufficiency

• Consent signed by the patient

• Patient with national health assurance

Exclusion Criteria:

• Contraindications in the not invasive ventilation
• Patient not volunteer for the realization of the spirometry
• Precautions for use of ß2 mimetic (engrave hyperthyroidism)
• Under guardianship patient or protection of justice
• Pregnant patient